Wolff Wiese Magana LLC Buys 1,514 Shares of Kenvue Inc. (NYSE:KVUE)

Wolff Wiese Magana LLC boosted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 2.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 78,513 shares of the company’s stock after purchasing an additional 1,514 shares during the period. Wolff Wiese Magana LLC’s holdings in Kenvue were worth $1,676,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Riverview Trust Co purchased a new position in Kenvue in the 3rd quarter worth approximately $30,000. Ashton Thomas Securities LLC purchased a new stake in shares of Kenvue during the third quarter valued at $35,000. Fortitude Family Office LLC increased its holdings in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after buying an additional 777 shares in the last quarter. Versant Capital Management Inc raised its position in Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after buying an additional 1,441 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators lifted its stake in Kenvue by 49.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after acquiring an additional 651 shares during the period. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Up 0.4 %

KVUE opened at $21.12 on Wednesday. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a market cap of $40.49 billion, a price-to-earnings ratio of 38.40, a price-to-earnings-growth ratio of 2.02 and a beta of 1.46. The firm’s fifty day moving average is $22.54 and its 200 day moving average is $21.65.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same period in the previous year, the firm earned $0.31 EPS. The firm’s revenue was down .4% compared to the same quarter last year. On average, sell-side analysts forecast that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.88%. The ex-dividend date of this dividend was Wednesday, November 13th. Kenvue’s payout ratio is 149.09%.

Analyst Ratings Changes

KVUE has been the subject of several research reports. Bank of America boosted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Barclays raised Kenvue to a “hold” rating in a report on Thursday, December 12th. Jefferies Financial Group assumed coverage on Kenvue in a report on Tuesday, September 24th. They issued a “buy” rating and a $27.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and cut their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus target price of $23.09.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.